CHIEF HF Trial was recently presented at the AHA 2021 meeting. It tested an #SGLT2Inhibitor #CANAGLIFLOZIN in #HEARTFAILURE.

CHIEF HF Trial or CANAGLIFLOZIN in HEART FAILURE which was recently presented at AHA 2021 is yet to be published.

If you were searching about CHIEF HF Trial or role of CANAGLIFLOZIN in HEART FAILURE you can find it in this video. The authors first presented its results in AHA 2021.

CTCR - MVS Trial. Tricuspid valve repair in patients undergoing Mitral Valve surgery. AHA 2021. NEJM 2021.

REVERSE- IT Trial. Bentracimab for ticagrelor reversal. AHA 2021

AVATAR Trial. Aortic valve replacement in Asymptomatic Severe Aortic Stenosis. AHA 2021.

How to manage patients with stable coronary artery disease. First part of the discussion - a look at all the contemporary data we have.

Best Antithrombotic Regimen after Watchman device? - JACC Interventions

In the latest edition of #JACC Interventions, this recently published study titled "Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population" compared the patients in United States undergoing PCI for stable #coronary artery disease (#CAD) with recently published #ISCHEMIA study. We got of new insights from data from this registry. Let's find out.

The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial (

#ACTIVATIONtrial) tested the strategy the #PCI before #TAVR Vs #TAVR without #PCI in patients with significant #CAD without significant #angina. Unfortunately the trial was terminated because of slow enrollment. Yet, it shed light on important issue in the holistic management of #TAVR patients. With newer evidences for management for #TAVR patients, more and more people are going to be screened for and offered #TAVR. Management of concomitant #CAD in these patients is an important issue. In this video we discuss about the #ActivationTrial and what to do for #CAD in patients undergoing #TAVR.

#EMPEROR PRESERVED trial was recently published in #NEJM in 2021. It was also presented at #ESC2021.

Heart Failure with Preserved Ejection Fraction (#HFpEF) is responsible of more than half of the cases of heart failure.

It is a difficult to diagnose and difficult to treat condition.

#Emplagliflozin and #dapagloflozin are 2 #SGLT2inhibitors have been found to be useful drugs in the management of #heart failure with reduced ejection fraction. The EMPEROR REDUCED and DAPA-HF trials have proven the efficacy of both these drugs in #heartfailure with reduced ejection (HFrEF).

The #EMPEROR PRESERVED trial tested that whether #emplagliflozin can be useful in the management of Heart Failure with Preserved Ejection Fraction (#HFpEF).